Clenbuterol
Clen
Clenbuterol (Clen) is a metabolic & fat loss research compound. Long-acting beta-2 adrenergic agonist. Raises cAMP in fat and muscle, increasing lipolysis and thermogenesis. In livestock it's a repartitioning agent; in humans the anabolic component is far weaker than the folklore suggests.
Clenbuterol quick facts
| Reported research dose (Oral) | 20–120mcg daily (research) |
| Route | Oral |
| Frequency | Daily during on-weeks |
| Half-life | ~26–36 hours — much longer than people assume, which is why 'take it in the morning' doesn't save your sleep. |
| Forms | Oral |
| Evidence level | Approved as an asthma drug outside the US; human body-composition data is thin |
| Other forms available | Injectable — dosed differently |
⚠️ The one people underrate: cardiac hypertrophy and arrhythmia. Beta-2 agonism at these doses is not benign, animal studies show myocardial changes, and there are human case reports of myocardial infarction and severe tachyarrhythmia. Taurine and potassium are commonly used for the cramping, which is a symptom of the problem rather than a fix. Not compatible with a beta blocker. Banned by WADA.
How Clenbuterol works
Long-acting beta-2 adrenergic agonist. Raises cAMP in fat and muscle, increasing lipolysis and thermogenesis. In livestock it's a repartitioning agent; in humans the anabolic component is far weaker than the folklore suggests.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get Clenbuterol
The evidence for Clenbuterol
Graded by what exists behind each claim.
✅ Clinically validated
- Approved for asthma in some countries and never in the US. The human clinical literature is respiratory, not anabolic — and the muscle effects come almost entirely from livestock and rodent work.
- Human case reports are substantial and consistent: tachycardia, palpitations, tremor, hypokalemia, and hospital presentations after accidental or deliberate overdose. There are also documented poisoning outbreaks from contaminated meat.
📊 Correlative data
- Long, heavy use in bodybuilding and a well-characterized practical profile: tremor and insomnia early, beta-2 receptor downregulation within about two weeks producing tolerance, and cramping from potassium and taurine depletion.
- Rodent work shows cardiac hypertrophy and fibrosis at high doses, and there is no long-term human follow-up of the population using it — which is precisely the data that would settle the cardiac question.
🧪 Theoretical / extrapolated
- A long-acting beta-2 adrenergic agonist. Beta-2 activation raises cAMP, which drives lipolysis in fat cells and increases metabolic rate; in muscle it appears to increase protein synthesis and reduce degradation.
- The very long half-life — roughly 26–36 hours — is the practical problem. It is why the stimulant effects accumulate and why receptor downregulation happens so fast.
- Beta-2 receptors are also on cardiac tissue, which is the direct mechanistic basis for the tachycardia and the hypertrophy concern. The cardiac effect is not a side effect of the fat-loss mechanism — it is the same receptor.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Clenbuterol actually does
Clenbuterol is a beta-2 agonist that was designed for animals and behaves in a human like a drug nobody titrated for one. Its receptor pharmacology is unremarkable. Its duration is the whole problem, and the card names it: roughly 26 to 36 hours.
The receptor and its two consequences. Beta-2 adrenoceptor occupancy activates Gs, raises cyclic AMP and activates protein kinase A. In airway smooth muscle that relaxes the airway. In skeletal muscle the same cascade shifts the balance between protein synthesis and breakdown — beta-agonists change the proliferation and differentiation of skeletal muscle cells in vitro Flavie Ouali 2021 — and in adipose tissue cAMP activates hormone-sensitive lipase and drives lipolysis. Those two effects are why the drug exists in this space. The third effect, in the heart, is why it is dangerous.
Why the half-life is the toxicology. A beta-2 agonist produces tachycardia, tremor and a fall in serum potassium. With a short-acting agonist those effects rise and fall within hours and the receptor has time between doses. With a 26 to 36 hour half-life, steady state is reached after roughly five half-lives — five to seven days — and daily dosing means accumulation. The person feels the first dose and does not feel the fourth one being added to the second and third. That is the pharmacokinetic reason clenbuterol poisoning presents days into use rather than immediately.
The cardiac argument, at the level of the tissue. Beta-2 receptors are present in human myocardium alongside beta-1. Chronic high-dose beta-agonism in animal models produces cardiac hypertrophy and myocyte injury — a hypertrophy driven by catecholamine signaling rather than by loading, which is the kind that is maladaptive. Reviews of unsupervised clenbuterol use in bodybuilding and athletics catalog the cardiovascular consequences directly Kataveni 2025. The muscle effect and the cardiac effect are the same receptor in two organs, and there is no dose that separates them.
Desensitization applies here too, and it is the reason for the folklore. Sustained agonism recruits GRKs and beta-arrestin and withdraws receptors from the surface Phan 2025. The two-weeks-on-two-weeks-off and escalating-dose patterns that circulate are attempts to outrun receptor downregulation. What they actually do is keep the cardiac exposure going while the peripheral effect fades, because the desensitization is not uniform across tissues.
Cell, rodent, human — and where it stops
Step one, cells: real and concentration-dependent. Beta-agonists change skeletal muscle cell proliferation and differentiation in culture Flavie Ouali 2021.
Step two, livestock, where the human evidence actually comes from. Clenbuterol and its relatives were developed as repartitioning agents for cattle and pigs — compounds that shift growth toward lean tissue and away from fat. A comparison of the beta-ligands used in cattle production sets out their structures, safety and biological effects Dilger 2021. This is the strongest efficacy evidence clenbuterol has, and it is in food animals at slaughter weight, measured as carcass composition. Stating that plainly is more useful than any extrapolation from it.
Step three, humans, and it is a toxicology literature rather than an efficacy one. The published human record on clenbuterol is dominated by poisoning: outbreaks from contaminated meat, and presentations after unsupervised use in bodybuilding and athletics Kataveni 2025. There is no randomized controlled trial of clenbuterol for body composition in healthy humans. Not a small one, not an old one. The compound's reputation rests entirely on animal repartitioning data and on self-report.
Step four, anti-doping. Clenbuterol is prohibited under the World Anti-Doping Agency list at all times, in and out of competition, with no inhaled exception of the kind that exists for some other beta-2 agonists. Detection of these agents in athletes has its own analytical literature Cricco 2025, and the residue-in-meat problem Dilger 2021 is the reason the contaminated-food defense exists at all — a defense which is occasionally true and routinely attempted.
Where the chain breaks, and it breaks early. (1) Cattle are dosed for weeks before slaughter and are not followed for cardiac outcomes, because they are slaughtered. A repartitioning endpoint in an animal that will not live long enough to develop a cardiomyopathy is not a safety result. (2) Species differ markedly in beta-receptor subtype distribution in the heart. (3) The human dose is unknown because no trial set one; every figure in circulation traces to self-report. (4) Material sold for this purpose is a research chemical of unverified concentration, and with a drug that accumulates over a week, a concentration error compounds daily.
What would have to be true, and how you would know it was not
Three predictions. The first two are safety measurements and the third is the one that tests whether the drug is doing anything for the reason people think.
1. If the drug is systemically active, potassium falls. beta-2 agonism drives the Na+/K+-ATPase and moves potassium into cells. A CMP carries potassium; measured at baseline and again 3 to 5 days in — deliberately after accumulation has begun rather than after the first dose — it is the cheapest objective evidence the compound is doing what a beta-2 agonist does. Magnesium serum in the same draw, because the combination is what turns a fast heart into an unstable one.
2. The falsification test is cardiac, and with this half-life it has to be repeated. Resting heart rate every morning for two weeks before and throughout. A resting heart rate that is still climbing on day five is accumulation, not tolerance, and it is the specific pattern that distinguishes this drug from a short-acting one. Troponin is the test if chest pain, unexplained breathlessness or syncope occurs, and an ECG belongs at baseline in anybody with a family history of sudden cardiac death.
3. The prediction that argues against the whole premise. If clenbuterol is anti-catabolic in humans the way it is repartitioning in cattle Dilger 2021, then lean mass should be preserved measurably. The measurement is a DEXA scan plus grip strength at baseline and at the end of a defined period, with body weight recorded alongside. If grip strength and lean mass are unchanged while resting heart rate is up 15 beats per minute, the compound has delivered the cardiac cost and none of the claimed benefit — and that is a result a person can generate about themselves in eight weeks.
What nobody has tested yet
Four things nobody has established, and the first is remarkable for a compound this widely used.
Nobody has run a randomized controlled trial of clenbuterol for body composition in healthy humans. Not one. The efficacy argument is cattle Dilger 2021 and the human literature is harm Kataveni 2025. Any page that describes a clenbuterol protocol is describing something no trial has ever measured.
Nobody has measured cardiac structure prospectively in human users. Echocardiography with strain imaging before, during and after a defined period of use in people who are going to use it anyway would be observational, feasible and ethically defensible, and it would answer whether the animal hypertrophy finding transfers. It has not been done.
Nobody has characterized the human dose-response. With a 26 to 36 hour half-life the difference between a tolerable and a toxic regimen is a matter of accumulation arithmetic, and no controlled pharmacokinetic study in humans at the doses actually taken exists to do that arithmetic with.
Nobody has quantified tissue-selective desensitization. The cycling folklore assumes that muscle and cardiac beta-2 receptors desensitize at the same rate. The biased-signaling literature Phan 2025 gives no reason to assume that. If cardiac receptors desensitize more slowly than muscle receptors, then every cycling pattern in circulation is optimizing for the wrong tissue, and the experiment that would show it is a receptor-density study in two tissues over time.
Clenbuterol — its own safety story, not its class's
Clenbuterol is not approved for human use in the United States for any indication. It is a veterinary and, in some countries, a human bronchodilator; in the US it exists as a research chemical and as a residue problem in meat Dilger 2021. The class block above does not describe it.
Cardiac toxicity is the headline and it is documented in people. Tachycardia, palpitations, chest pain, arrhythmia and myocardial injury are catalogued in the review of unsupervised use in bodybuilding and athletics Kataveni 2025. Poisoning outbreaks from contaminated meat produced the same picture in people who took no drug deliberately — which is as clean a demonstration of dose-related toxicity as this field ever gets, because the exposed population had no expectation of an effect.
Hypokalemia is the mechanism that converts tachycardia into an arrhythmia, and with a drug that accumulates over five to seven days it deepens rather than resolving between doses. Add a diuretic, a stimulant, a period of vomiting or diarrhea, or a low magnesium, and the margin disappears.
Tremor, anxiety, insomnia and sweating are not side effects to push through. They are the systemic signature of the same receptor occupancy that is acting on the heart, and their intensity tracks the exposure. The card's own note is the practical version: with a 26 to 36 hour half-life, taking it in the morning does not protect the night.
Anti-doping status. Prohibited at all times under the World Anti-Doping Agency list, with no inhaled exemption Cricco 2025. Because trace residues can arise from meat Dilger 2021, analytical thresholds and case adjudication in this specific drug are contested — but a tested athlete taking it deliberately will fail.
What this page will not do. Print a dose, a cycle length, or a taper. There is no human efficacy trial to base one on, the compound accumulates for a week, and the organ that receives the excess is the heart.
Sources read for this page
- Kataveni S, et al. Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences. Cureus 2025 · PMID 40575216
- Dilger AC, et al. Comparison of beta-ligands used in cattle production: structures, safety, and biological effects. Journal of Animal Science 2021 · PMID 34337648
- Flavie Ouali BE, et al. Beta-agonist drugs modulate the proliferation and differentiation of skeletal muscle cells in vitro. Biochemistry and Biophysics Reports 2021 · PMID 34041371
- Cricco R, et al. Performance-Enhancing Effects of Inhaled Medications: Implications for Heart, Muscle Function, and Doping Detection in Athletes. Journal of Functional Morphology and Kinesiology 2025 · PMID 41440783
- Phan NTN, et al. Biased Signaling and Its Role in the Genesis of Short- and Long-Acting beta2-Adrenoceptor Agonists. Biochemistry 2025 · PMID 40773134
Clenbuterol — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Beta-2 agonists (clenbuterol, albuterol) and central stimulants (tesofensine) share one predicted problem: cardiac load. Raised heart rate, palpitations, tremor and insomnia are the mechanism showing up, not an idiosyncratic reaction.
- Beta-2 agonists drive potassium into cells, so hypokalemia is predicted — and low potassium is itself arrhythmogenic, which is how a stimulant side effect becomes a cardiac one.
- Clenbuterol's half-life is long (well over a day in humans), so it accumulates across daily dosing. The dose that felt fine on day one is not the exposure you have on day five.
- Beta-2 receptors downregulate within around two weeks — the thermogenic effect fades while the cardiac effect persists longer. That is the worst possible combination and it is why escalating the dose to chase the original effect is the dangerous move.
What has actually been reported
- Cardiac hypertrophy is documented in animal models at sustained high doses. Human data comes largely from poisoning case reports — tachycardia, tremor, hypokalemia, and arrhythmia.
- Tesofensine raised blood pressure and heart rate in trials, which is part of why its development for obesity stalled.
How to reduce the risk
Same mechanism as the prediction.
- Take a resting heart rate every morning. It moves before anything else does and it is a better early signal than any quarterly panel.
- Potassium and magnesium intake matter here specifically because of the intracellular shift — this is one of the few places a supplement addresses the actual mechanism rather than a vague deficiency.
- Do not escalate to recover a faded effect. The fade is receptor downregulation, and the answer is a break, not more.
What it does to your bloodwork
A fact about the assay.
- Potassium and magnesium (a CMP covers potassium). Blood pressure and resting heart rate are the real monitoring and they are free.
Don't run this if
- You have any arrhythmia, structural heart disease, or uncontrolled hypertension.
- You are already taking another stimulant, including high-dose caffeine — the cardiac effects are additive and people do not count coffee.
The honest unknown
- Whether the cardiac hypertrophy seen in animals occurs at the doses and durations used in humans is not established, and it would be difficult to study ethically.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Clenbuterol — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Clenbuterol moves on your bloodwork
Expected direction, not a measured one.
- TSH (Thyroid-Stimulating Hormone) — ↓ expected to fall
Exogenous thyroid hormone or a thyromimetic suppresses TSH by feedback. A suppressed TSH here is the expected consequence, not evidence of thyroid disease.
What to do: TSH alone is uninterpretable on these. Run free T3 and free T4 with it or the panel means nothing. - Free T3 (Triiodothyronine) — ↑ expected to rise
Rises with dosing, and this is the number driving both the benefit and the risk.
What to do: The gap between 'metabolically effective' and 'losing muscle and beating up your heart' is narrow. Test, don't estimate. - Complete Blood Count (CBC) with Differential — ◆ worth watching
Not the marker itself — but resting heart rate and blood pressure are the real-time readouts of over-dosing here, and they move before any lab does.
What to do: Take a resting heart rate every morning. It is a better early signal than a quarterly panel. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Uncouplers and strong thermogenics raise metabolic demand and can stress liver enzymes.
What to do: Baseline liver function before, and again at 8 weeks.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Clenbuterol in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Clenbuterol
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
Clenbuterol — frequently asked questions
What is Clenbuterol?
Clenbuterol (Clen) is a metabolic & fat loss research compound. Long-acting beta-2 adrenergic agonist. Raises cAMP in fat and muscle, increasing lipolysis and thermogenesis. In livestock it's a repartitioning agent; in humans the anabolic component is far weaker than the folklore suggests.
Is the full Clenbuterol protocol on this page?
The reported research dose is on this page, along with how Clenbuterol works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Clenbuterol?
Clenbuterol has an approximate half-life of ~26–36 hours — much longer than people assume, which is why 'take it in the morning' doesn't save your sleep., which is part of what determines how often it's dosed.
What's the evidence behind Clenbuterol?
Current evidence level: Approved as an asthma drug outside the US; human body-composition data is thin. Clenbuterol is offered for research purposes only and is not an approved medicine.
Clenbuterol inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Clenbuterol is used for
Clenbuterol appears under 1 goal in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
Clenbuterol is the direct-lipolysis arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.